
November 13, 2017 - By Stephen Andrade
Among 4 analysts covering Cryolife (NYSE:CRY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cryolife had 9 analyst reports since April 13, 2016 according to SRatingsIntel. The stock of Cryolife Inc (NYSE:CRY) has “Buy” rating given on Wednesday, June 15 by Lake Street. The firm has “Buy” rating given on Tuesday, July 25 by Northland Capital. The stock has “Buy” rating by Canaccord Genuity on Sunday, October 8. Canaccord Genuity maintained Cryolife Inc (NYSE:CRY) rating on Tuesday, October 31. Canaccord Genuity has “Buy” rating and $25.0 target. The firm has “Buy” rating given on Friday, February 17 by Ladenburg Thalmann. Canaccord Genuity initiated Cryolife Inc (NYSE:CRY) rating on Wednesday, April 13. Canaccord Genuity has “Buy” rating and $14 target. As per Tuesday, July 25, the company rating was maintained by Canaccord Genuity. Northland Capital maintained Cryolife Inc (NYSE:CRY) on Monday, May 1 with “Buy” rating. Northland Capital initiated the stock with “Outperform” rating in Monday, January 9 report. See Cryolife Inc (NYSE:CRY) latest ratings:31/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0 Maintain08/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0 Maintain25/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0000 Maintain25/07/2017 Broker: Northland Capital Rating: Buy New Target: $23.5000 MaintainManikay Partners Llc decreased Bhp Billiton Plc (BBL) stake by 43.45% reported in 2017Q2 SEC filing. Manikay Partners Llc sold 487,918 shares as Bhp Billiton Plc (BBL)’s stock declined 8.96%. The Manikay Partners Llc holds 635,000 shares with $19.53 million value, down from 1.12 million last quarter. Bhp Billiton Plc now has $108.07B valuation. The stock declined 0.64% or $0.24 reaching $37.38 per share. About 687,566 shares traded. BHP Billiton plc (ADR) (NYSE:BBL) has risen 31.15% since November 13, 2016 and is uptrending. It has outperformed by 14.45% the S&P500.CryoLife, Inc. is a medical device maker and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The company has market cap of $633.18 million. The Firm operates through two divisions: Medical Devices and Preservation Services. It has a 67.71 P/E ratio. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. About 55,163 shares traded. Cryolife Inc (NYSE:CRY) has risen 60.65% since November 13, 2016 and is uptrending. It has outperformed by 43.95% the S&P500.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.


var data = "63557954";
document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="8925061741"></ins>')

(adsbygoogle = window.adsbygoogle || []).push({});
(adsbygoogle = window.adsbygoogle || []).push({});